Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celltex allogeneic adipose-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Celltex Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Celltex Therapeutics Corporation's allogeneic adipose-derived mesenchymal stem cells (AdMSCs) are an investigational cell therapy developed for the treatment of severe COVID-19 symptoms. This "off-the-shelf" therapy utilizes mesenchymal stem cells isolated from donor adipose (fat) tissue, which are expanded to therapeutic doses and administered via intravenous infusion. The cells function through immunomodulatory and anti-inflammatory mechanisms, migrating to areas of inflammation and injury. Once at the site, they act primarily through paracrine effects, releasing bioactive molecules that help suppress overactive immune responses, such as the cytokine release syndrome associated with severe COVID-19, while supporting the body's inherent repair mechanisms. This approach is distinct from the company's autologous products and is intended for use when using a patient's own cells is not feasible.
- Other names
- allogeneic adipose-derived mesenchymal stem cellsallogeneic AdMSCsCelltex AdMSCsallogeneic adipose-derived stem cells
Beyond the preview
Go deeper on Celltex allogeneic adipose-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celltex allogeneic adipose-derived mesenchymal stem cells.